Research Grade Felvizumab (DVV02804)

Description

Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB 209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb, RSV19. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999). RSHZ19 (Felvizumab) RSV This antibody was

Catalog No.

DVV02804

Host species

Humanized

Species reactivity

HRSV-A

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

1 mg/ml

Purity

>95% by SDS-PAGE.

Clonality

Monoclonal

Isotype

IgG1, kappa

Applications

Research Grade Biosimilar

Target

F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

XtenCHO

Accession

P03420

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

SB 209763, HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB 209763, RSV19, CAS: 167747-20-8, Human Respiratory Syncytial Virus (HRSV)

Note

For research use only. Not suitable for clinical or therapeutic use.